|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0012920,
umls-concept:C0017262,
umls-concept:C0017337,
umls-concept:C0030297,
umls-concept:C0035668,
umls-concept:C0085983,
umls-concept:C0086418,
umls-concept:C0185117,
umls-concept:C0442726,
umls-concept:C0443199,
umls-concept:C0701185,
umls-concept:C1510438,
umls-concept:C1511790,
umls-concept:C1709793,
umls-concept:C2911684
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1992-6-2
|
|
pubmed:abstractText |
RNA/PCR quantitation method was developed to determine DNA Topoisomerase I(Topo I)-specific mRNA in order to study its gene expression in CPT-11 sensitive, acquired- or native-resistant human pancreatic tumor cell lines. The results were supported by Northern blotting and Western blotting analyses. Acquired-resistant cells have shown decreased levels of Topo I mRNA, compared with their parental cells. On the contrary, in the wild type cells no correlation was shown between sensitivity and gene expression. On the other, specific Topo I activity of the native resistant cell lines was fairly lower than that of sensitive cell lines, suggesting that immunoreactive Topo I protein contains low levels of active form enzyme which could be targets of CPT-11 in these native-resistant ones. Finally, the different mechanisms might be operative between acquired- and native-resistant tumor cells.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0006-291X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
30
|
|
pubmed:volume |
184
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
618-25
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:1315526-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:1315526-Base Sequence,
pubmed-meshheading:1315526-Blotting, Northern,
pubmed-meshheading:1315526-Camptothecin,
pubmed-meshheading:1315526-Cell Division,
pubmed-meshheading:1315526-Cell Line,
pubmed-meshheading:1315526-DNA Topoisomerases, Type I,
pubmed-meshheading:1315526-Drug Resistance,
pubmed-meshheading:1315526-Gene Expression,
pubmed-meshheading:1315526-Gene Expression Regulation, Enzymologic,
pubmed-meshheading:1315526-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:1315526-Humans,
pubmed-meshheading:1315526-Molecular Sequence Data,
pubmed-meshheading:1315526-Oligodeoxyribonucleotides,
pubmed-meshheading:1315526-Pancreatic Neoplasms,
pubmed-meshheading:1315526-Polymerase Chain Reaction,
pubmed-meshheading:1315526-RNA, Messenger
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
Differential expression of DNA topoisomerase I gene between CPT-11 acquired- and native-resistant human pancreatic tumor cell lines: detected by RNA/PCR-based quantitation assay.
|
|
pubmed:affiliation |
Division of Chemotherapy, National Kyushu Cancer Center, Fukuoka, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
